Sensorion Reports 2026 Half-Year Results and Updates

Sensorion, a clinical-stage biotech company specializing in hearing loss therapies, reported its 2026 half-year results. The company highlighted progress in their SENS-601 gene therapy program for GJB2-related hearing loss. Clinical Trial Applications were submitted in France, Canada, and are expected in the U.S. and Australia by the end of 2026. Fast Track authorization was granted in France, allowing the Phase I/II HearConnex trial to proceed.

SENS-601's trial is set for early 2027. This therapy addresses common forms of hearing loss using a single-vector AAV-based approach. Financially, Sensorion reported €88 million in cash as of June 30, 2026, an increase from €47.5 million the previous year, ensuring operations until late 2027. R&D expenses rose to €16.4 million. Leadership changes were announced as Fred Chereau took over as CEO in June 2026.